CN109620857A - Peanut coat active component and its preparing the application in anti-fat antidiabetic medicine - Google Patents
Peanut coat active component and its preparing the application in anti-fat antidiabetic medicine Download PDFInfo
- Publication number
- CN109620857A CN109620857A CN201910040231.8A CN201910040231A CN109620857A CN 109620857 A CN109620857 A CN 109620857A CN 201910040231 A CN201910040231 A CN 201910040231A CN 109620857 A CN109620857 A CN 109620857A
- Authority
- CN
- China
- Prior art keywords
- group
- active component
- peanut coat
- coat active
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000017060 Arachis glabrata Nutrition 0.000 title claims abstract description 101
- 241001553178 Arachis glabrata Species 0.000 title claims abstract description 101
- 235000010777 Arachis hypogaea Nutrition 0.000 title claims abstract description 101
- 235000018262 Arachis monticola Nutrition 0.000 title claims abstract description 101
- 235000020232 peanut Nutrition 0.000 title claims abstract description 101
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 230000003178 anti-diabetic effect Effects 0.000 title claims description 5
- 239000003472 antidiabetic agent Substances 0.000 title claims description 5
- 235000013305 food Nutrition 0.000 claims abstract description 40
- 239000008103 glucose Substances 0.000 claims abstract description 36
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 35
- 210000004369 blood Anatomy 0.000 claims abstract description 31
- 239000008280 blood Substances 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000011347 resin Substances 0.000 claims abstract description 5
- 229920005989 resin Polymers 0.000 claims abstract description 5
- 230000002745 absorbent Effects 0.000 claims abstract description 4
- 239000002250 absorbent Substances 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 51
- 241000699670 Mus sp. Species 0.000 abstract description 17
- 208000008589 Obesity Diseases 0.000 abstract description 11
- 235000020824 obesity Nutrition 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 8
- 102000011690 Adiponectin Human genes 0.000 abstract description 3
- 108010076365 Adiponectin Proteins 0.000 abstract description 3
- 102000016267 Leptin Human genes 0.000 abstract description 3
- 108010092277 Leptin Proteins 0.000 abstract description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract description 3
- 229940039781 leptin Drugs 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000010172 mouse model Methods 0.000 abstract description 2
- 230000019491 signal transduction Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 238000011697 diabetes animal model Methods 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000000967 suction filtration Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- 238000012545 processing Methods 0.000 description 30
- 150000002632 lipids Chemical class 0.000 description 22
- 150000001720 carbohydrates Chemical class 0.000 description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 16
- 235000014633 carbohydrates Nutrition 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000003651 drinking water Substances 0.000 description 9
- 235000020188 drinking water Nutrition 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 7
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 244000005709 gut microbiome Species 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- -1 D- (+)-inositol Chemical compound 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241001156739 Actinobacteria <phylum> Species 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 2
- 241000605059 Bacteroidetes Species 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940041290 mannose Drugs 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of peanut coat active component, by alcohol steep peanut coat, suction filtration, concentration, with macroporous absorbent resin separation, collect fraction obtain.In anti-fat, diabetes experiment made on the living, the present invention confirms that the adjustable adiponectin of peanut coat active component and leptin signaling pathway generate the effect of losing weight and blood glucose by diabetes animal model, the food ration of experimental obesity mice and diabetes B model mice can be significantly reduced, weight and blood glucose value improve significantly to fat and diabetes clinical symptoms tool.It can be applied in food fat in preparation prevention and treatment and diabetes, health food and drug.
Description
Technical field
The invention belongs to the medicine food fields of compound, are related to peanut coat active component and its are preparing anti-fat, anti-sugar
Urinate the application in medicine.
Background technique
Fat and diabetes as a kind of global prevalence disease have become 21st century maximum public health problem it
One, overweight more than 1,900,000,000 adults according to World Health Organization in 2014,600,000,000 or more people is fat.Obesity is to lead to non-wine
The risk factor that essence fatty liver, diabetes B, cardiovascular disease and cancer sharply increase, all these diseases are not only serious
The quality of life of the mankind is influenced, and shortens the service life of the mankind.Especially diabetes B, if cannot get in time and have
The easily concurrent such as coronary heart disease of the treatment of effect, cerebrovascular disease, nephrosis, the complication such as retinopathy, these complication, which become, to threaten
The main reason for diabetic life., therefore keep the blood glucose level close to normal range (NR) for preventing diabetic complication
It is particularly significant.
Fat and diabetes are a kind of endocrine metabolism diseases that the cause of disease is sufficiently complex, are since internal insulin is absolute
Or a kind of endocrine metabolism disease caused by relative deficiency, mark are weight gain and chronic raised blood glucose water
It is flat.Although current most for the treatment of obesity, the oral hypoglycemic drugs of diabetes have certain effect, but easily rebound after there is drug withdrawal,
The disadvantages of side effect is more.
The active component in Chinese medicine peanut coat source is a kind of oligosaccharides and Flavonoid substances, it has been found that peanut coat active component
Apparent weight-reducing and drop are generated to experimental obesity mice and diabetes B mouse by adjusting adiponectin and leptin signaling pathway
The effect of blood glucose.
Summary of the invention
The object of the present invention is to provide a kind of peanut coat active component, which passes through following preparation method
Obtain: 60% ethanol water (volume ratio) extracts peanut coat 2 times, 1 hour for the first time, second 0.5 hour, filters later,
It is concentrated into the 1/50 of original volume, is separated later with macroporous absorbent resin HP-20, eluting solvent is 40% ethanol water
(volume ratio) collects fraction, this fraction is peanut coat active component.Peanut coat active component mainly includes saccharide portion and non-
Carbohydrate fraction.Saccharide portion is by arabinose, xylose, D- (+)-inositol, myo- inositol, mannose, glucose and galactolipin group
At, and molar ratio is 3:6.9:1:1.5:3.2:21.5:3.8.Non-saccharide part is made of Polyphenols, mainly includes A type or Type B
Dimer, tripolymer and the tetramer (table 1) of procyanidine.
It is a further object to provide the peanut coat active components to prepare anti-fat, antidiabetic medicine
In application.
It is also another object of the present invention to provide the peanut coat active components to reduce fat, reduction blood glucose value in preparation
Health care product or food in application.
In anti-fat, diabetes experiment made on the living, the adjustable adiponectin of above-mentioned peanut coat active component and Leptin signaling
Access generates the effect of losing weight and blood glucose, and experimental obesity mice and 2 types can be significantly reduced in discovery peanut coat active group
The food ration of diabetic mice, weight and blood glucose value (see Fig. 7).
The peanut coat active component can prepare pharmaceutically acceptable carrier or diluent according to any conventional process.Here
The pharmaceutically acceptable carrier refers to the pharmaceutical carrier of pharmaceutical field routine, such as diluent, excipient are in this way etc., fill out
Fill agent such as starch, sucrose, microcrystalline cellulose etc.；Adhesive such as starch slurry, hydroxypropylcellulose, gelatin, polyethylene glycol etc.；Wetting agent
Such as magnesium stearate, superfine silica gel powder, polyethylene glycols；The poly- sorb rouge of sorbefacient, lecithin etc., surfactant Bai Luosha
Nurse, fatty acid sorbitan, poly- sorb rouge etc., in addition it can which other adjuvants such as flavouring agent, sweetener are added in the composition
Deng.
The dosage form of administration can be tablet, pill, pulvis, dispersible tablet, sachets, elixir, suspension, emulsion, solution
Agent, syrup, aerosol, soft capsule, hard capsule, aseptic parenteral solution, liniment or suppository.It can be made into routine, quick-release is sustained or prolongs
Slowbreak is put.
Peanut coat active component of the invention can be given by all means, including oral, muscle, subcutaneously, abdominal cavity, intravenous
Deng.
The raw material that the present invention uses are that source is easy to get, resourceful peanut coat, and peanut coat is main in traditional Chinese medicine
It is used to treat hemophilia, primary and secondary thrombocytopenic purpura and hepatorrhagia etc..We use natural products
Separation, purification technique handle peanut coat, and by simple, effective extraction and macroreticular resin separation have just obtained flower
Raw clothing active component.The active component is mainly made of oligosaccharides and different types of procyanidine.The active component is not only to height
The obesity mice of rouge material induction has significant antiobesity action, and also has very well for material high in fat induction diabetes B mouse
Antidiabetic effect, drug effect exists in 80mg/kg dosage with the drug melbine for the treatment of diabetes listed
Drug effect is suitable when 140mg/kg dosage.And without apparent toxic side effect.
Detailed description of the invention
Fig. 1 is peanut coat active component carbohydrate fraction hydrogen spectrum (deuterated methanol is as solvent).
Fig. 2 is peanut coat active component carbohydrate fraction carbon spectrum (deuterated methanol is as solvent).
Fig. 3 is the non-carbohydrate fraction hydrogen spectrum of peanut coat active component (deuterated methanol is as solvent).
Fig. 4 is the non-carbohydrate fraction carbon spectrum of peanut coat active component (deuterated methanol is as solvent).
Fig. 5 is peanut coat active component carbohydrate fraction monosaccharide component analysis GC/MS map.The mixing of standard monosaccharide sample
Object (A) spectrogram and peanut coat active component spectrogram (B).Peak mark: 1, rhamnose；2, trehalose；3, arabinose；4, xylose；
5, D- (+)-inositol；6, inositol；7, mannose；8, glucose；9, galactolipin.
Fig. 6 is the non-carbohydrate fraction high resolution mass spectrum figure of peanut coat active component.
Fig. 7 is influence of the peanut coat active component to experimental obese mouse weight.In figure:**The peanut coat activity of P < 0.01
Component processing group vs model control group,***The peanut coat active component processing group vs model control group of P < 0.001,#P < 0.05 is high in fat
Feed group vs Normal group,##The high lipid food group vs Normal group of P < 0.01,###The high lipid food group vs normal control of P < 0.01
Group.Every group of number of animals: n=10.ND is chow diet group, and HFD is high lipid food group, and HFD+PSE is that high lipid food group adds peanut
The grouping of clothing active group.
Fig. 8 is influence of the peanut coat active component to experimental obesity mice food ration.In figure:**The peanut coat of P < 0.01 is living
Property component processing group vs model control group,***The peanut coat active component processing group vs model control group of P < 0.001,#P < 0.05 is high
Rouge feed group vs Normal group,##The high lipid food group vs Normal group of P < 0.01,###The high lipid food group of P < 0.01 vs is normally right
According to group.Every group of number of animals: n=10.ND is chow diet group, and HFD is high lipid food group, and HFD+PSE is that high lipid food group adds flower
Raw clothing active group grouping.
Fig. 9 is influence of the peanut coat active component to experimental obesity mice amount of drinking water.In figure:**The peanut coat of P < 0.01 is living
Property component processing group vs model control group,***The peanut coat active component processing group vs model control group of P < 0.001,#P < 0.05 is high
Rouge feed group vs Normal group,##The high lipid food group vs Normal group of P < 0.01,###The high lipid food group of P < 0.01 vs is normally right
According to group.Every group of number of animals: n=10.ND is chow diet group, and HFD is high lipid food group, and HFD+PSE is that high lipid food group adds flower
Raw clothing active group grouping.
Figure 10 is influence of the peanut coat active component to experimental adipose tissues.In figure: C indicates normal control
Group, DM-C indicate diabetic controls group, and Met indicates melbine processing group；PSE indicates peanut coat active component processing group.###P
< 0.001 diabetic controls group VS Normal group；*The drug-treated group vs diabetic controls group of P < 0.05,**At the drug of P < 0.01
Reason group vs diabetic controls group, n=10.
Figure 11 is influence of the peanut coat active component to experimental type 2 diabetes mellitus mouse fasting blood-glucose.Wherein: C is indicated just
Normal control group, DM-C indicate diabetic controls group, and Met indicates melbine processing group；PSE indicates the processing of peanut coat active component
Group.###The diabetic controls group VS Normal group of P < 0.001；*The drug-treated group vs diabetic controls group of P < 0.05,**P<0.01
Drug-treated group vs diabetic controls group, n=10.
Figure 12 is the influence of peanut coat active component experimental type 2 diabetes mellitus mouse food ration.Wherein: C indicates normal right
According to group, DM-C indicates diabetic controls group, and Met indicates melbine processing group；PSE indicates peanut coat active component processing group.*
P < 0.05vs model control group,**P < 0.01vs model control group, n=10.
Figure 13 is influence of the peanut coat active component to experimental type 2 diabetes mellitus mouse amount of drinking water.Wherein: C indicates normal
Control group, DM-C indicate diabetic controls group, and Met indicates melbine processing group；PSE indicates the processing of peanut coat active component
Group.*P < 0.05,**The drug-treated group vs diabetic controls group of P < 0.01, n=10.
Figure 14 is the influence that peanut coat active component changes experimental type 2 diabetes mellitus mouse weight.Wherein: C is indicated just
Normal control group, DM-C indicate diabetic controls group, and Met indicates melbine processing group；PSE indicates the processing of peanut coat active component
Group.###The diabetic controls group VS Normal group of P < 0.001；*The drug-treated group vs diabetic controls group of P < 0.05,**P<0.01
Drug-treated group vs diabetic controls group, n=10.
Figure 15 is influence of the peanut coat active component to experimental type 2 diabetes mellitus glucose tolerance in mice.Wherein: (A) is to gavage
The variation of blood glucose in diabetic mice value after peanut coat active component and glucose；It (B) is corresponding area under the drug-time curve.C
Indicate that Normal group, DM-C indicate diabetic controls group, Met indicates melbine processing group；PSE indicates peanut coat active group
Divide processing group.###The diabetic controls group vs Normal group of P < 0.001；***The drug-treated group vs diabetic controls group of P < 0.001,
N=7.
Figure 16 is influence of the peanut coat active component to experimental type 2 diabetes mellitus mouse and insulin resistance.Wherein:
(A) be blood glucose in diabetic mice value after gavaging peanut coat active component and glucose variation；It (B) is corresponding Drug-time curve
Lower area.C indicates that Normal group, DM-C indicate diabetic controls group, and Met indicates melbine processing group；PSE indicates peanut
Clothing active component processing group.###The diabetic controls group vs Normal group of P < 0.001；*P<0.05,***The drug-treated of P < 0.001
Group vs diabetic controls group, n=7.
Figure 17 is influence of the peanut coat active component to experimental type 2 diabetes mellitus mouse intestinal microbial flora.Wherein:
It (A) is diabetic mice intestinal microflora cluster analysis result after gavaging peanut coat active component and glucose；It (B) is sample
Species profiling histogram in product Phylum categorization levels.C indicates that Normal group, DM indicate diabetic controls group, Met
Indicate melbine processing group；PSE indicates peanut coat active component processing group, n=7.
Specific embodiment
The present invention is further described in conjunction with the accompanying drawings and embodiments.
1 peanut coat active component of embodiment is extracted
It takes 60% alcohol steep peanut coat 2 times, 1 hour for the first time, second 0.5 hour, filters later, be concentrated into substance
Long-pending 1/50 is separated with macroporous absorbent resin HP-20 later, and eluting solvent is 40% ethyl alcohol, collects fraction, this fraction is
For peanut coat active component.
2 peanut coat active component constituent analysis of embodiment
Experimental method:
Peanut coat active component is divided into two parts, condition by high performance liquid chromatography (HPLC) are as follows: Develosil ODS-
UG-5 (20 × 250mm of φ), Nomura Chemical column, 6ml/min flow velocity, 0-15min, 18% methanol isocratic elution are collected
For carbohydrate components；15-25min, 18%-100% methanol elution gradient, 25-40min, 100% methanol isocratic elution are collected as
Non- carbohydrate components.Later by wave spectrum analysis, high resolution mass spectrum and chemical derivatization method are to carbohydrate fraction and non-carbohydrate fraction
Component analyzed.
Experimental result:
By composing the analysis (Fig. 1-4) of nuclear magnetic spectrogram to this two parts hydrogen spectrum and carbon, confirm that this two parts is respectively carbohydrate
Part and non-carbohydrate fraction.Later by carbohydrate fraction hydrolysis, acetylation carry out GC/MS analysis, by with standard sample acetylation
Sample is compared later, determine carbohydrate fraction mainly by arabinose, xylose, D- (+)-inositol, myo- inositol, mannose,
Glucose and galactolipin composition, and molar ratio is 3:6.9:1:1.5:3.2:21.5:3.8 (Fig. 5).Non-saccharide part passes through high-resolution
Mass spectral analysis (Fig. 6) and (Yu, JM et al., Peanut skin procyanidins:Composition is compared with document
and antioxidant activities as affected by processing,Journal of Food
Composition and Analysis 19 (2006) 364-371), as a result, it has been found that be made of Polyphenols, mainly include A type or
Dimer, tripolymer and the tetramer (table 1) of person's Type B procyanidine.
The non-carbohydrate part of compounds composition of 1 peanut coat active component of table.
The influence for the endomorphy type mouse that 2 peanut coat active component of embodiment induces high lipid food
Experimental method:
Six week old male mices are divided into five groups, every group ten by the present embodiment.Normal group gavages water and normal diet.
High fat diet (HFD) control group gavages and the solvent of processing group equivalent and free choice feeding high lipid food.High lipid food adds peanut coat
Active component group gavages peanut coat active component by the dosage of 4,80 and 160 mg kg of body weights/day respectively and height is freely eaten
Rouge feed and drinking-water.Experiment periods are 6 weeks, record weight, food ration, amount of drinking water weekly.After the last administration, animal is deprived of food but not water
12h takes blood examination to survey the indexs such as blood glucose, triglycerides, cholesterol, creatinine, AST, ALT in serum, and taken the heart, liver, pancreas, spleen,
The tissue such as kidney, fat, muscle, brain.
Experimental result: high lipid food group mouse weight, food ration is compared with Normal group, mouse weight and food ration
(Fig. 7, Fig. 8) is obviously increased, still, the amount of drinking water of high lipid food group significantly reduces (Fig. 9).Peanut coat active component processing group with
High in fat group compares, and mouse weight incrementss significantly reduce (Fig. 7) in dose relationship, and food ration and amount of drinking water are significantly reduced
(Fig. 8, Fig. 9), and each tissue weight of each group is compared, it is found that the fat of peanut coat processing group and model control group
And liver weight there are significant differences (Figure 10) therefore, peanut coat active component have apparent antiobesity action.
The research of the preparation method of 3 experimental type 2 diabetes mellitus mouse of embodiment
High lipid food is the major way of inducing obesity diabetes B model, correctly to prepare experimental type 2 diabetes mellitus
Mouse, the present embodiment take the mode of Long-term Feeding high lipid food to construct diabetes B pathological model.
Experimental method:
Experimental animal has been divided into control group and model group by the present embodiment.Control group gives chow diet, and model group is given
High lipid food (is all provided by Shanghai Slac Experimental Animal Co., Ltd.).Breeding cycle is 5 months, is taken the photograph to animal weekly
Appetite, amount of drinking water, weight are measured.Last week of modeling is to mouse fasting and measures the blood glucose value of mouse, when weight is obvious
Increase, mouse of the blood glucose value greater than 9 or more is judged as diabetes B mouse.
Experimental result:
After high lipid food is fed 5 months, mouse weight and blood glucose are obviously increased.And blood glucose value is both greater than 9 or more.Therefore,
It is used as the drug efficacy study that diabetes B animal model carries out peanut coat active component.
Influence mouse model preparation of the 4 peanut coat active component of embodiment to experimental type 2 diabetes mellitus mouse:
Animal packet:
Healthy male mice 10 and 50, diabetes B model are taken, are randomly divided into, Normal group, diabetic controls
Group, positive controls (melbine), peanut coat processing group (high, in, low dose group).Normal group gives chow diet,
The feed of remaining each group is high lipid food (being provided by Shanghai Slac Experimental Animal Co., Ltd.).Test period is 4 weeks, just
Normal control group and model control group stomach-filling water.Positive controls gavage melbine, and peanut coat active component processing group fills respectively
The peanut coat active component of 10,80,160mg/kg dosage is taken, every other week fasting 12h, tail portion takes blood, measures change of blood sugar value.
And measure daily food ration and daily amount of drinking water.After the last administration, animal is deprived of food but not water 12h, and blood examination is taken to survey in serum
The indexs such as blood glucose, triglycerides, cholesterol, creatinine, AST, ALT, and taken the groups such as the heart, liver, pancreas, spleen, kidney, fat, muscle, brain
It knits.
Experimental result:
After administration, peanut coat active ingredient doses group 80mg/kg and 160mg/kg has compared with model control group blood glucose value
Significant difference (Figure 11).(table 2) additionally is compared to index each in serum, it is found that peanut coat active ingredient doses
80mg/kg is compared with the blood glucose value in the serum of model control group for group, there is significant difference.In food ration and amount of drinking water, flower
Raw clothing active ingredient doses group 80mg/kg and 160mg/kg also have significant difference (Figure 12,13) compared with modeling group.And it is right
Each tissue weight of each group compares, it is found that raw clothing active ingredient doses group 80mg/kg and 160mg/kg are compared with modeling group
There are significant difference (tables 3, Figure 14) for fat weight.
Influence of the 2. peanut coat active component of table to experimental 2 type obesity mice Serum Indexes
In this test, ALT represents glutamic-oxalacetic transaminease, and AST represents paddy the third special project enzyme, and TG represents three rouge of triacylglycerol, TC
Total cholesterol is represented, GLU represents blood glucose；MET represents melbine#, ##, ###Indicate diabetes group P < 0.05, P compared with normal group
<0.01,P<0.001；*, * *, * * *Expression diabetes group P < 0.05 compared with peanut coat active component processing group, P < 0.01, P <
0.001；Animal specimen number is 10.
Influence of the 3. peanut coat active component of table to experimental 2 type obesity mice internal organs
MET represents melbine, and PSE represents peanut coat active component,##, ###Indicate diabetes group compared with normal group P <
0.05,P<0.01,P<0.001；*, * *, * * *Expression diabetes group P < 0.05 compared with peanut coat active component processing group, P < 0.01,
P<0.001；Animal specimen number is 10.
The above result shows that peanut coat active component can reduce the blood glucose of experimental type 2 diabetes mellitus mouse, and significantly subtract
More drink symptoms eaten in light diabetes B mice clinical performance more.
5 peanut coat active component of embodiment is to the sugar tolerance of experimental type 2 diabetes mellitus mouse and the shadow of insulin sensitivity
It rings
Experimental method:
Oral glucose tolerance test (OGTT) and intraperitoneal injection insulin are used after gavaging peanut coat active component 4 weeks
Tolerance test (ITT) measurement blood glucose value must change.Specific test method is as follows: after experimental animal fasting 12 hours, gavaging difference
The melbine of dosage gavages 2 gram/glucose in peanut coat active component 15 minutes, measures 0,15,30 with blood sugar test paper,
The variation of 60,90,120 minutes blood glucose values.
In addition, the experimental animal of fasting 4 hours is injected intraperitoneally the insulin of 0.4 unit of every mouse, blood sugar test paper is used
Measurement 0,15,30,60,90 minutes blood glucose values of measurement must change.
Experimental result:
After mouse gavaging glucose, the blood glucose value and sugar of peanut coat active component 10mg/kg, 80mg/kg and 160mg/kg
Urine disease model group compares, and blood glucose value is substantially reduced, and AUC area under the curve significantly reduces (Figure 15).Further, mouse is being infused
After penetrating insulin, blood glucose value is substantially reduced, and AUC area under the curve significantly reduces (Figure 16).These results of study show 2 property glycosurias
Sick mouse has obtained apparent improvement to the sensibility of sugared tolerance and insulin.
Influence of the 6 peanut coat active component of embodiment to experimental type 2 diabetes mellitus mouse intestinal microbial flora.
Influence of the peanut coat active component to the intestinal microflora of experimental type 2 diabetes mellitus mouse
Experimental method:
After gavaging peanut coat active component and melbine 6 weeks, disinfects in alcohol and adopt after mouse cage is cleaned up
Collect each group stool in mice sample 100mg or so (2-3).DNA is extracted, by specified sequencing region, to the 16S rDNA V4 of sample
Region is expanded.And PE250 sequencing analysis is carried out using 2500 instrument of Hiseq.Experimental result carries out species complexity in group
Species difference is analyzed between analysis and group.
Experimental result:
Mouse intestinal microbial flora cluster analysis result shows, peanut coat active ingredient doses group 10mg/kg and model
Control group intestinal microflora is similar, however gives 80mg/kg peanut coat active component and melbine group 6 Zhou Houtu mouse
Intestinal microflora forms (17.A) similar to blank control group.In addition, sclerine in model control group intestinal microflora
Bacterium door (Firmicutes) significant raising compared with blank control group with the ratio of Bacteroidetes (Bacteroidetes), is filling
It takes 80mg/kg peanut coat active component and after melbine 6 weeks, which reduces (Figure 17 .B) compared to conspicuousness.And flower
Raw clothing active ingredient doses group 80mg/kg and Proteobacteria (Proteobacteria) in melbine group intestinal microflora
Ratio significantly reduces (Figure 17 .B) compared with model control group.In addition, model control group is compared with blank control group, mouse intestinal
Occur actinomyces (Actinobacteria) (Figure 17 .B) in microbial flora, but give 80mg/kg peanut coat active component and
After melbine 6 weeks, actinomyces (Actinobacteria) are horizontal consistent with blank control group in mouse intestinal microbial flora,
And 10mg/kg peanut coat active component does not improve this phenomenon (Figure 17 .B).
The above result shows that peanut coat active component can regulate and control experimental type 2 diabetes mellitus mouse intestinal microbial environment
Stable state.
Claims (5)
1. a kind of peanut coat active component, which is characterized in that obtained by following preparation method: 60% alcohol steep peanut coat 2
It is secondary, it 1 hour for the first time, second 0.5 hour, filters later, is concentrated into the 1/50 of original volume, uses macroporous absorbent resin later
HP-20 is separated, and eluting solvent is 40% ethyl alcohol, collects fraction, this fraction is peanut coat active component.
2. a kind of peanut coat active component described in claim 1 is preparing anti-fat, in antidiabetic medicine application.
3. a kind of peanut coat active component described in claim 1 reduces health care product or food fat, that reduce blood glucose value in preparation
Application in product.
4. application according to claim 2, which is characterized in that the dosage form of the drug is solid or liquid preparation, administration
Approach is enteron aisle or non-bowel.
5. application according to claim 3, which is characterized in that the dosage form of the health care product or food is solid or liquid system
Agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910040231.8A CN109620857B (en) | 2019-01-16 | 2019-01-16 | Peanut coat active component and application thereof in preparation of anti-obesity and anti-diabetic drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910040231.8A CN109620857B (en) | 2019-01-16 | 2019-01-16 | Peanut coat active component and application thereof in preparation of anti-obesity and anti-diabetic drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109620857A true CN109620857A (en) | 2019-04-16 |
| CN109620857B CN109620857B (en) | 2021-05-25 |
Family
ID=66061110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910040231.8A Active CN109620857B (en) | 2019-01-16 | 2019-01-16 | Peanut coat active component and application thereof in preparation of anti-obesity and anti-diabetic drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109620857B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116509918A (en) * | 2023-05-12 | 2023-08-01 | 浙江大学 | Application of three natural product combinations in preparation of medicines for treating non-alcoholic fatty liver disease |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101665482A (en) * | 2009-09-24 | 2010-03-10 | 山东省花生研究所 | Method for purifying proanthocyanidins in peanut coat |
| CN102488218A (en) * | 2011-12-22 | 2012-06-13 | 湖南长沙远航生物制品有限公司 | Method for extracting and preparing high-content peanut coat polyphenol from peanut coat |
| CN103349671A (en) * | 2013-08-02 | 2013-10-16 | 甘肃凯源生物技术开发中心 | Resveratrol and spirulina composition and preparations and preparation method thereof |
| CN103622135A (en) * | 2013-11-26 | 2014-03-12 | 山东鲁花集团有限公司 | Method for extracting polyphenols from peanut skins |
| CN103877144A (en) * | 2013-05-02 | 2014-06-25 | 杭州耐奇睿生物医药科技有限公司 | Application of peanut coat active component and composition comprising peanut coat active component |
| CN107382948A (en) * | 2017-08-17 | 2017-11-24 | 山东金胜粮油集团有限公司 | A kind of preparation method of high-purity peanut scarlet OPC |
| CN108285458A (en) * | 2018-02-28 | 2018-07-17 | 浙江天草生物科技股份有限公司 | The method that procyanidine A2 is extracted from peanut coat |
| CN109111420A (en) * | 2018-08-28 | 2019-01-01 | 湖南大三湘茶油股份有限公司 | A kind of preparation method of glucosidase procyanidins |
-
2019
- 2019-01-16 CN CN201910040231.8A patent/CN109620857B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101665482A (en) * | 2009-09-24 | 2010-03-10 | 山东省花生研究所 | Method for purifying proanthocyanidins in peanut coat |
| CN102488218A (en) * | 2011-12-22 | 2012-06-13 | 湖南长沙远航生物制品有限公司 | Method for extracting and preparing high-content peanut coat polyphenol from peanut coat |
| CN103877144A (en) * | 2013-05-02 | 2014-06-25 | 杭州耐奇睿生物医药科技有限公司 | Application of peanut coat active component and composition comprising peanut coat active component |
| CN103349671A (en) * | 2013-08-02 | 2013-10-16 | 甘肃凯源生物技术开发中心 | Resveratrol and spirulina composition and preparations and preparation method thereof |
| CN103622135A (en) * | 2013-11-26 | 2014-03-12 | 山东鲁花集团有限公司 | Method for extracting polyphenols from peanut skins |
| CN107382948A (en) * | 2017-08-17 | 2017-11-24 | 山东金胜粮油集团有限公司 | A kind of preparation method of high-purity peanut scarlet OPC |
| CN108285458A (en) * | 2018-02-28 | 2018-07-17 | 浙江天草生物科技股份有限公司 | The method that procyanidine A2 is extracted from peanut coat |
| CN109111420A (en) * | 2018-08-28 | 2019-01-01 | 湖南大三湘茶油股份有限公司 | A kind of preparation method of glucosidase procyanidins |
Non-Patent Citations (6)
| Title |
|---|
| ADRIANO COSTA DE CAMARGO，等: "Phenolic Profle of Peanut By‑products: Antioxidant Potential and Inhibition of Alpha‑Glucosidase and Lipase Activities", 《JOURNAL OF AMERICAN OIL CHEMISTS’SOCIETY》 * |
| 刘大川，等: "花生红衣提取物中白藜芦醇、原花色素分离工艺的研究", 《食品科学》 * |
| 姬娜，等: "花生种皮原花青素结构的初步鉴定", 《中国粮油学报》 * |
| 曾画艳，等: "花青素抑制肥胖作用机制研究进展", 《食品科技》 * |
| 王兴娜，等: "花生衣中天然产物的制备与分析研究", 《食品科技》 * |
| 陈洋，等: "RP-HPLC-ESI-MS/MS分离鉴定花生红衣原花青素A型和B型二聚体", 《食品科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116509918A (en) * | 2023-05-12 | 2023-08-01 | 浙江大学 | Application of three natural product combinations in preparation of medicines for treating non-alcoholic fatty liver disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109620857B (en) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2077851B1 (en) | A pharmaceutical composition comprising cordycepin for the treatment and prevention of obesity | |
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN101229181A (en) | Medicine compounds for curing diabetes and complications thereof | |
| US6451353B1 (en) | Fagopyrum cymosum (Trev.) Meisn composition, method to prepare and analyze the same and uses thereof | |
| CN101181373B (en) | Cortex moutan valid target pharmaceutical combination, preparation method and application thereof | |
| US11253566B2 (en) | Composition for ameliorating, or treating depression and anxiety disorder comprising Fraxinus rhynchophylla extract as effective ingredient | |
| CN109620857A (en) | Peanut coat active component and its preparing the application in anti-fat antidiabetic medicine | |
| CN109125315A (en) | Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity | |
| CN101474346B (en) | Longstamen onion bulb extract as well as preparation method and application thereof | |
| JP6156795B2 (en) | Composition for suppressing adipocyte differentiation, reducing fat accumulation in adipocytes and / or promoting adiponectin secretion from adipocytes | |
| US20100261663A1 (en) | Compositions Containing Harpagoside and Paeoniflorin and Methods for Treatment of Conditions Associated with Pain, Inflammation, Arthritis and Symptoms Thereof | |
| CN109381455A (en) | With the composition for adjusting blood glucose, blood lipid and blood pressure function | |
| CN102335338B (en) | Chinese medicinal compound preparation for improving parkinson disease brain neurotransmitter metabolism | |
| CN105560308B (en) | Flower of JINHUAKUI is preparing the application in the product for preventing and treating prostatic disorders | |
| KR100390766B1 (en) | Active fraction having inhibitory effects on fatty acid synthase isolated from piper longum | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| AU9778698A (en) | A (fagopyrum cymosum) (trev.) meisn composition, method to prepare and analyze the same and uses thereof | |
| CN104582730B (en) | A kind of method improving Metabolism of Mitochondria function and application | |
| CN111249271A (en) | Medicament for treating diabetes and preparation method and application thereof | |
| CN105998196A (en) | Blood sugar decreasing healthcare pharmaceutical composition prepared from fiveleaf gynostemma herb | |
| KR100895500B1 (en) | Composition for the prevention and treatment of fatty liver diseases containing honokiol as an active ingredient | |
| CN101143203A (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN111246849A (en) | Composition for enhancing learning and memory ability | |
| CN102846679A (en) | Composition with weight losing effect | |
| CN110123827A (en) | A kind of pharmaceutical composition and its preparation method and application treated by metabolic disorder associated diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231026 Address after: No.98 Baoheng Road, Shenzhou City, Hengshui City, Hebei Province, 052800 Patentee after: Hebei Kaixiang Health Technology Co.,Ltd. Address before: 310058 Yuhang Tang Road, Xihu District, Hangzhou, Zhejiang 866 Patentee before: ZHEJIANG University |